Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745096 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL26091641 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL2183439 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL20567660 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL4540684 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL4538607 | 1.00 | PPARA (0.58) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL1363883 | 0.92 | PPARA (0.51) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL28155239 | 0.86 | PPARA (0.56) | PPARAGAAPLA2G4BTP53TSHR | |
| SCHEMBL1743906 | 0.86 | MAPT (0.53) | GAATP53TSHRL3MBTL1HDAC1 | |
| SCHEMBL558993 | 0.86 | MAPT (0.53) | GAATP53TSHRL3MBTL1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110945017-B | Bifunctional compounds | 诺和诺德股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-116490212-A | GLP-1 prodrugs and uses thereof | 诺和诺德股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11130794-B2 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2021-09-28 | — | — | US | disclosed |
| US-20200231645-A1 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2020-07-23 | — | — | US | disclosed |
| EP-3655427-A1 | BIFUNCTIONAL COMPOUNDS | Novo Nordisk A/S (DK) | 2020-05-27 | — | — | EP | disclosed |
| CN-110945017-A | Bifunctional compounds | 诺沃挪第克公司 | 2020-03-31 | — | — | CN | disclosed |
| WO-2019016306-A1 | BIFUNCTIONAL COMPOUNDS | NOVO NORDISK A/S (DK) | 2019-01-24 | — | — | WO | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | PPARA 179/4885GAA 770/4885PLA2G4B 1170/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | PPARA 250/4885GAA 801/4885PLA2G4B 1242/4885 |
| US-11130794-B2 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | PPARA 159/4885GAA 618/4885PLA2G4B 252/4885 |
| US-20200231645-A1 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | PPARA 159/4885GAA 618/4885PLA2G4B 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.